The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study
Open accessAbstract
Background People with type 1 diabetes are at elevated risk of mortality and cardiovascular disease, yet current guidelines do not consider age of onset as an important risk stratifier. We aimed to examine how age at diagnosis of type 1 diabetes relates to excess mortality and cardiovascular risk.Methods We did a nationwide, register-based cohort study of individuals with type 1 diabetes in the Swedish National Diabetes Register and matched controls from the general population. We included patients with at least one registration between Jan 1, 1998, and Dec 31, 2012. Using Cox regression, and with adjustment for diabetes duration, we estimated the excess risk of all-cause mortality, cardiovascular mortality, non-cardiovascular mortality, acute myocardial infarction, stroke, cardiovascular disease (a composite of acute myocardial infarction and stroke), coronary heart disease, heart failure, and atrial fibrillation. Individuals with type 1 diabetes were categorised into five groups, according to age at diagnosis: 0-10 years, 11-15 years, 16-20 years, 21-25 years, and 26-30 years.Findings 27 195 individuals with type 1 diabetes and 135 178 matched controls were selected for this study. 959 individuals with type 1 diabetes and 1501 controls died during follow-up (median follow-up was 10 years). Patients who developed type 1 diabetes at 0-10 years of age had hazard ratios of 4·11 (95% CI 3·24-5·22) for all-cause mortality, 7·38 (3·65-14·94) for cardiovascular mortality, 3·96 (3·06-5·11) for non-cardiovascular mortality, 11·44 (7·95-16·44) for cardiovascular disease, 30·50 (19·98-46·57) for coronary heart disease, 30·95 (17·59-54·45) for acute myocardial infarction, 6·45 (4·04-10·31) for stroke, 12·90 (7·39-22·51) for heart failure, and 1·17 (0·62-2·20) for atrial fibrillation. Corresponding hazard ratios for individuals who developed type 1 diabetes aged 26-30 years were 2·83 (95% CI 2·38-3·37) for all-cause mortality, 3·64 (2·34-5·66) for cardiovascular mortality, 2·78 (2·29-3·38) for non-cardiovascular mortality, 3·85 (3·05-4·87) for cardiovascular disease, 6·08 (4·71-7·84) for coronary heart disease, 5·77 (4·08-8·16) for acute myocardial infarction, 3·22 (2·35-4·42) for stroke, 5·07 (3·55-7·22) for heart failure, and 1·18 (0·79-1·77) for atrial fibrillation; hence the excess risk differed by up to five times across the diagnosis age groups. The highest overall incidence rate, noted for all-cause mortality, was 1·9 (95% CI 1·71-2·11) per 100 000 person-years for people with type 1 diabetes. Development of type 1 diabetes before 10 years of age resulted in a loss of 17·7 life-years (95% CI 14·5-20·4) for women and 14·2 life-years (12·1-18·2) for men.Interpretation Age at onset of type 1 diabetes is an important determinant of survival, as well as all cardiovascular outcomes, with highest excess risk in women. Greater focus on cardioprotection might be warranted in people with early-onset type 1 diabetes.Funding Swedish Heart and Lung Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The risk of diabetesrelated complications also remains notably high for all people with type 1 diabetes.1,2”
From The future of type 1 diabetes therapy (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“life expectancy remains reduced for individuals diagnosed with type 1 diabetes before age 10 years compared with both people diagnosed after 10 years and people without type 1 diabetes.1,2”
From The future of type 1 diabetes therapy (2025) · cites this paper as [1]
In the citing paper
“A recent risk tool, developed based on the Scottish/Swedish Diabetes Registry and validated in the Swedish National Diabetes Register can provide individualized risk predictions.793”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [793]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
External review and validation of the Swedish national inpatient register
Ludvigsson, J. F., Andersson, E., Ekbom, A., Feychting, M., Kim, J.-L., Reuterwall, C., Heurgren, M., & Olausson, P. O. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-450 · Cited by 5,055
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761
Ahlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I
Paneni, F., Beckman, J. A., Creager, M. A., & Cosentino, F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht149 · Cited by 1,455
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citationDiabetic cardiovascular autonomic neuropathy
Vinik, A. I., & Ziegler, D. (2007) · Circulation · doi:10.1161/circulationaha.106.634949 · Cited by 1,255
Excess Mortality among Persons with Type 2 Diabetes
Tancredi, M., Rosengren, A., Svensson, A., Kosiborod, M., Pivodic, A., Guðbjörnsdóttir, S., Wedel, H., Clements, M. A., Dahlqvist, S., & Lind, M. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504347 · Cited by 1,026
Self-citationGlycemic Control and Excess Mortality in Type 1 Diabetes
Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408214 · Cited by 964
Self-citation
Cited by
Sorted by citations
Items 601–700 of 801
Risque cardiovasculaire du patient diabétique de type 1
Vergès, B. L. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.03.004 · Cited by 1
Real-World Experience With Automated Insulin Pump Technology in Veterans With Type 1 Diabetes
Amole, M. (2021) · Federal Practitioner · doi:10.12788/fp.0156 · Cited by 1
COVID-19 and Type 1 diabetes in Sweden
(2020) · doi:10.31038/edmj.2020424 · Cited by 1
“In spite of this active treatment those who have got the diagnosis Type 1 diabetes in childhood have a much shorter expected length of life than a reference population [16].”
BackgroundFritsch, M., Nagl, K., Rojacher, T., Dorninger, L., Hofer, S. E., & Fröhlich-Reiterer, E. E. (2021) · Pädiatrie & Pädologie · doi:10.1007/s00608-021-00889-3 · Cited by 2
“Lebensjahr) einenunabhängigenRisikofaktor für makrovaskuläre Erkrankungen darstellt [6].”
BackgroundŠumnı́k, Z., Konečná, P., Venháčová, P., Neumann, D., Škvor, J., Pomahačová, R., Strnadel, J., Průhová, Š., Petruželková, L., Vosáhlo, J., et al. (2022) · Česko-slovenská pediatrie · doi:10.55095/cspediatrie2022/008 · Cited by 1
Precision Exercise and Physical Activity for Diabetes
Boulé, N. G., & Yardley, J. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_13 · Cited by 1
Riesgo cardiovascular en diabetes tipo 1 y tipo 2: Diferencias, similitudes y reflexiones
de Victoria, E. O. M., & Viñals, C. (2022) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2022.07.001 · Cited by 1
Cardiovascular risk in type 1 and type 2 diabetes: Differences, similarities and insights
Victoria, E. O. M. D., & Doménech, C. V. (2022) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2022.08.004 · Cited by 1
Aktueller Stand der Insulinpumpentherapie in der Kinderdiabetologie
Berge, T. V. D., Reschke, F., & Biester, T. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1780-3779 · Cited by 1
Excess mortality and cardiovascular disease risk in type 1 diabetes
SNAITH, J. R., Holmes-Walker, D. J., Girgis, C. M., & Greenfield, J. R. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33050-2 · Cited by 1
Tian, F., Huang, S., Xu, W., Feng, X., Chen, J., Wang, X., & Huang, Q. (2022) · Research Square · doi:10.21203/rs.3.rs-2346001/v1 · Cited by 1
Automated Insulin Delivery for People With Type 1 Diabetes and High HbA1c: Is It Time?
Wheeler, B. J., & Boucsein, A. (2024) · Diabetes Care · doi:10.2337/dci24-0076 · Cited by 1
Kashyap, S. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101461 · Cited by 1
Fuentes‐Mendoza, J. M., Gonzales‐Valdivieso, R., Concepción‐Zavaleta, M. J., & Cortez-Sandoval, M. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2522223 · Cited by 1
Medikamentöse Therapie von Fettstoffwechselstörungen bei Patienten mit Typ-2-Diabetes
Müller‐Wieland, D., & Parhofer, K. G. (2018) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-124740
Type 1 Diabetes: The Earlier the Onset, the Worse the Prognosis
Krumholz, H. M., & Sm (2018) · Journal watch · doi:10.1056/nejm-jw.na47353
Medikamentöse Therapie von Fettstoffwechselstörungen bei Patienten mit Typ-2-Diabetes
Müller‐Wieland, D., & Parhofer, K. G. (2019) · Gefäßmedizin Scan - Zeitschrift für Angiologie Gefäßchirurgie diagnostische und interventionelle Radiologie · doi:10.1055/a-0858-3922
In Stufen zu möglichst niedrigem LDL-Cholesterin bei Diabetes
Stirban, O. A. (2019) · Info Diabetologie · doi:10.1007/s15034-019-1461-2
Dépistage des complications du diabète de type 1 chez l’enfant
Briet, C., & Allix, I. (2018) · Elsevier eBooks · doi:10.1016/b978-2-294-74942-1.00016-1
Lee, M. Y., & Maahs, D. M. (2019) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2019.06.040
A kardiovaszkuláris kockázat csökkentése 1-es típusú diabetes mellitusban, felnőttkorban
Hosszúfalusi, N., & Kempler, M. (2019) · Diabetologia Hungarica · doi:10.24121/dh.2019.12
“Mindezek alapján a szerzők felhívják a figyelmet, arra, hogy a kardiovaszkuláris kockázat csökkentése kiemelten fontos korai életkorban kezdődő T1DM esetén.(5)”
Methods in Childhood Health: Chronic Disease Epidemiology and Age Estimation
Gesuita, R., Ferrante, L., Skrami, E., & Carle, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-33832-9_26
¿Los protocolos experimentales son un símil real de la diabetes humana?
Moreno-Cortés, M. L., Gutiérrez‐García, A. G., & Contreras, C. M. (2020) · CienciaUAT · doi:10.29059/cienciauat.v14i2.1289
Use of routinely collected data to assess outcomes in people with diabetes
Holman, N. (2020) · Enlighten: Theses (The University of Glasgow) · doi:10.5525/gla.thesis.78967
Actualités des diabètes de l’enfant en 2020
Tubiana‐Rufi, N. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.06.003
Mesa 1: Diabetes mellitus tipo 1 y enfermedad cardiovascular
González, L., Chertkoff, A., Burgos, M. A., Trifone, L., Sanabria, H. D., Koleff, C. K., Roccatagliata, L. E., Rama, V., Pomares, M. L., Suppo, M., et al. (2020) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v54i2sup.251
Trends in HbA1c and other biochemical outcomes of individuals with newly diagnosed type 1 diabetes
O’Carroll-Lolait, A., Urwin, A., Doughty, I., Schofield, J. D., Thabit, H., & Leelarathna, L. (2020) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-020-02434-w
Kiss, Z., Rokszin, G., Abonyi‐Tóth, Z., Jermendy, G., Kempler, P., Barkai, L., & Wittmann, I. (2020) · Diabetologia Hungarica · doi:10.24121/dh.2020.22
Obesity in diabetes. Cardiovascular outcomes and risk factor trajectories
Edqvist, J. (2021) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Marcovecchio, M. L., & Papadopoulou‐Marketou, N. (2021) · Springer eBooks · doi:10.1007/978-3-642-27843-3_102-1
Brown, R. (2021) · Enlighten: Theses (The University of Glasgow) · doi:10.5525/gla.thesis.82173
Iklé, J. M., & Maahs, D. M. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.02.033
Patterns of care of subjects with type 1 and type 2 diabetes according to their cardiovascular risk
Pintaudi, B. (2021) · The Journal of AMD · doi:10.36171/jamd20.23.4.12
Heart geometry in climacteric syndrome on the background of type 1 diabetes mellitus
Гончарова, О. А. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.17.4.2021.237343
Júnior, G. D. F. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.6.2021.tde-31082021-094515
Венгржиновская, О. И., Bondarenko, I. Z., Shatskaya, O. A., Kosharnaia, R. S., & Shestakova, M. V. (2021) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2021-36-3-78-86
Perinatal risk factors for type 1 diabetes in children and adolescents
Lindell, N. (2021) · Linköping University medical dissertations · doi:10.3384/diss.diva-180918
Competitive strategy for an Indian natural stone trader
van Poppelen, M. (2009)
When should Lipoprotein(a) be measured?
Inácio, I. M. R., Azevedo, T., Alves, M., Dantas, R., & Guimarães, J. (2021) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632211061258
“In the section “When should Lp(a) be measured?”, the authors refer to the Hyperlipidaemia Education and Atherosclerosis Research Trust United Kingdom (HEART UK) recommendations to perform Lp(a) measurement in five specific groups: (1) those with a personal or family history of premature atherosclerotic cardiovascular…”
BackgroundKardiovaskuläre Risiken in der 4.–6. Lebensdekade mit Diabetes mellitus Typ 1
Lee-Barkey, Y. H., Stratmann, B., & Tschöpe, D. (2022) · Der Diabetologe · doi:10.1007/s11428-021-00854-5
“Mit ihm konnte das 10-Jahres-Risiko für kardiovaskuläre Ereignisse mit großer Zuverlässigkeit vorhergesagt werden, wobei die Risikoabschätzung bei Diagnosestellung des T1DM im Kindesalter besonders effektiv ist.”
BackgroundInfluentialDyslipidämien: Aktuelles Lipid-Management
Müller‐Wieland, D., Lehrke, M., Lebherz, C., Schütt, K. S., & Marx, N. (2020) · Deutsches Ärzteblatt · doi:10.3238/persdia.2020.05.15.02
Metabolic and cardiovascular risk factors associated with type 1 Diabetes Mellitus in pediatric age
Araújo, M., & Correia, C. C. (2022) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.26497/ar210013
[The Multidisciplinary Management of Type 2 Diabetes: an Integrated Care Model]
Berra, C., & Pradelli, L. (2021) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v22i2s.1512
Gea, I. L., Chacón, R. P., Jiménez, A. B. A., Loro, M. M., Ceballos, L. T., Hinojosa, J. M. J., Gómez‐Perea, A., & Siguero, J. P. L. (2022) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2021.10.010
Methods for Measuring Blood Pressure and Applications to Diabetes
Vazeou, A., & Stergiou, G. S. (2022) · Biomarkers in disease · doi:10.1007/978-3-030-81303-1_37-1
Typ-1-Diabetes und kardiovaskuläre Risikofaktoren bei Kindern und Jugendlichen
Drozd, I., Weiskorn, J., Lange, K., & Kordonouri, O. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1713-2438
Probiotika für die Mundgesundheit
Wolf, T. G. (2022) · Der Freie Zahnarzt · doi:10.1007/s12614-022-0315-9
Feng, W., Huang, R., Lu, S., Shan, T., Wang, H., Wang, S., & Liu, Y. (2020) · doi:10.2196/preprints.22240
von Herrath, M., & Coppieters, K. T. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735949131.793562193
JENDLE, J. H., Ampudia‐Blasco, F. J., Füchtenbusch, M., & Pozzilli, P. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.1.1.12
Evaluación y manejo del riesgo cardiovascular residual en el paciente con diabetes
Orna, J. A. G., Toro, J. J. O., & Miranda, C. M. P. (2020) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2020.06.003
Manifestation eines Typ-1-Diabetes verzögern?
Bonifacio, E. E., & Gemulla, G. (2022) · Diabetes aktuell · doi:10.1055/a-1772-8411
Rivera‐Mancilla, E., Villanueva‐Castillo, B., Altamirano‐Espinoza, A. H., Manrique‐Maldonado, G., & Villalón, C. M. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175138
Marcovecchio, M. L., & Papadopoulou‐Marketou, N. (2022) · Springer eBooks · doi:10.1007/978-3-030-52719-8_102
Methods for Measuring Blood Pressure and Applications to Diabetes
Vazeou, A., & Stergiou, G. S. (2022) · Biomarkers in disease · doi:10.1007/978-3-031-08014-2_37
Brinck, A. P. J., Hagström, A. P. E., Nåtman, J., Franzén, S., Eeg‐Olofsson, K., Nathanson, A. P. D., & Eliasson, B. (2022) · doi:10.2337/figshare.21224384.v1
Self-citationDiabetestechnologie bei Kindern und Jugendlichen mit Diabetes mellitus Typ 1
Rami-Merhar, B. M. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00975-5
“kardiovaskuläre Ereignisse) assoziiert ist und Mädchen/Frauen im Vergleich zu Knaben/Männern ein noch höheres Risiko haben [7].”
BackgroundGlucose: An Ongoing Risk Factor for Myocardial Infarction
Khan, I. (2022) · Cardiology Research and Cardiovascular Medicine · doi:10.29011/2575-7083.100083
Impacts of Diabetes Type 1 on the Heart of Children
Shaban, A. M. A., & Alrimawi, S. S. (2022) · Scholars Academic Journal of Pharmacy · doi:10.36347/sajp.2022.v11i11.001
Rochmah, N., Wijani, L. A. A., Faizi, M., Hisbiyah, Y., Perwitasari, R. K., Utamayasa, I. K. A., Kusumastuti, N. P., & Irwanto, I. (2022) · Journal of Comprehensive Pediatrics · doi:10.5812/compreped-131806
“Globally, the incidence of T1DM is increasing, and it is anticipated that over 90,000 children are afflicted with T1DM annually (29).”
BackgroundCommentary to "How to Treat Peripheral Arteriovenous Malformations"
Candela, E. (2023) · Angiología · doi:10.20960/angiologia.00486
Choi, I. H., Yeom, S. W., Kim, S., You, J., Kim, J. S., & Kim, M. S. (2023) · Children · doi:10.3390/children10020358
“A recent study [27] reported that the age at diagnosis of type 1 diabetes is an essential factor in mortality due to cardiovascular disease.”
BackgroundAnderzén, J. (2023) · Linköping University medical dissertations · doi:10.3384/9789180750325
Matejko, B., Tota, Ł. M., Morawska-Tota, M., Pałka, T., Malecki, M. T., & Klupa, T. (2023) · Research Square · doi:10.21203/rs.3.rs-2607369/v1
Aktueller Stand der Insulinpumpentherapie in der Kinderdiabetologie
Berge, T. V. D., Reschke, F., & Biester, T. (2023) · Pädiatrie up2date · doi:10.1055/a-1981-4040
“[2] Rawshani A, Sattar N, Franzén S et al.”
BackgroundAkpalu, J., Essuman, V. A., Amoaku, W. M. K., Abaidoo, B., Essuman, A., Hayfron-Benjamin, C. F., Barnes, N. A., Tagoe, N. N., Asare, G. A., Ndanu, T. A., et al. (2023) · Ghana Medical Journal · doi:10.4314/gmj.v57i2.2
“Individuals diagnosed with diabetes at a younger age have a much higher risk of developing ASCVD than those diagnosed later in life.(30) ASCVD is a major cause of mortality among adults with onset of DM at a young age, particularly for T2DM.”
BackgroundAdjunct Drug Treatment to Reduce Vascular Disease in People with Diabetes
Jenkins, A. J. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_29
Inflammation and Cardiovascular Disease in Diabetes
Manasi, S. S. (2023) · Clinical Diabetology · doi:10.5603/dk.a2023.0018
Caramalho, Í., Matoso, P., Ligeiro, D., Paixão, T., Sobral, D., Fitas, A., Limbert, C., Demengeot, J., & Penha-Gonçalves, C. (2023) · medRxiv · doi:10.1101/2023.07.23.23293034
Editorial: Daily challenges around physical exercise, nutrition and medication in type 1 diabetes
Moser, O., & Dovč, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1259535
Highlights from the Diabetes UK Professional Conference 2023
Bishop, K. (2023) · Practical Diabetes · doi:10.1002/pdi.2470
Genetic causality between type 1 diabetes and arrhythmia: a two-sample Mendelian randomization studyPreprint
Liu, Y., Rao, J., Hu, W., Zhang, Y., Yu, Y. S., Wang, P., Chen, X., & Wang, Z. (2023) · Research Square · doi:10.21203/rs.3.rs-3151462/v1
Mul, D., Varkevisser, R. D. M., Aanstoot, H., Dekker, P., Birnie, E., Boersma, H. E., Boesten, L. S. M., Brugts, M. P., van Dijk, P. R., Geelhoed-Duijvestijn, P. H. L. M., et al. (2023) · medRxiv · doi:10.1101/2023.08.17.23294197
Agewall, S., Roldán, V., & Marín, F. R. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780192869227.003.0027
Özde, Ş., Aktüre, G., Yavuzyılmaz, F., Arslanoğlu, İ., Özde, C., Kayapınar, O., Kaya, A., Coşkun, G., & Sayın, A. E. (2023) · Research Square · doi:10.21203/rs.3.rs-3498018/v1
Does size matter? Hospital volume and resource use in paediatric diabetes care
de Vries, S. A. G., Bak, J. C. G., Mul, D., Wouters, M. W. J. M., Nieuwdorp, M., Verheugt, C. L., & Sas, T. (2023) · Diabetic Medicine · doi:10.1111/dme.15260
Iklé, J. M., Addala, A., & Maahs, D. M. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch69
Klare, W.-R. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01121-5
Growth Status and Glycemic Control of Diabetic Children in a Tertiary Care Hospital in Dhaka City
Naz, F., Tayyeb, S., Zabeen, B., & Choudhury, A. Y. (2024) · Mugda Medical College Journal · doi:10.3329/mumcj.v6i2.71392
Metabolic Control, Morbidity and Mortality in Type 1 Diabetes with Onset in Childhood/Adolescence
Samuelsson, J. (2024) · Linköping University medical dissertations · doi:10.3384/9789180755269
Zhao, Y., Quan, E., Zeng, T., Huang, Z., Luo, Y., Peng, L., Li, S., Liu, J., Chong, Y., & Cao, H. (2024) · Figshare · doi:10.6084/m9.figshare.24995489
ANALYSIS OF REGULATORY AND LEGAL SUPPORT FOR THE PREVENTION OF DIABETES MELLITUS IN CHILDREN
Pocheniuk, K. V., & Голованова, І. А. (2024) · Актуальні проблеми сучасної медицини Вісник Української медичної стоматологічної академії · doi:10.31718/2077-1096.24.2.182
Network Cluster Analysis of PPI and Phenotype Ontology for Type 1 Diabetes Mellitus.
Zaeifi, D., & Azarnia, M. (2024) · PubMed Central · doi:10.30498/ijb.2024.361840.3502
“Children with T1DM are at an increased risk of mortality, other complications, and cardiovascular problems (11).”
BackgroundType 1 diabetes: Prevention and screening in focus
Milicic, T. J., Jotić, A., Lukić, L., Macesic, M. V., Gajović, J. S., Stoiljkovic, M. M., Milovancevic, M. M., Rafailović, Đ., Božović, A., Radisavljević, N., et al. (2024) · Medicinska istrazivanja · doi:10.5937/medi57-49676
Acute Myocardial Infarction in a Seven-Year-Old Child With Type 1 Diabetes: A Rare Case Report
Hajaj, H., Elouali, A., Ghanam, A., Rkain, M., & Babakhouya, A. (2024) · Cureus · doi:10.7759/cureus.62909
“Rawshani et al. demonstrated that individuals with T1DM who developed the disease before the age of 10 had a 30-fold increased risk of coronary heart disease and AMI in early adulthood [11].”
BackgroundDo Type 1 and Type 2 Diabetes Have the Same Vascular Complications?
Cho, Y. K. (2024) · Journal of Korean Diabetes · doi:10.4093/jkd.2024.25.2.62
Transitioning Adolescents and Young Adults with Type 1 Diabetes to Adulthood
D’Amico, R., & Buschur, E. (2024) · Springer eBooks · doi:10.1007/978-3-031-54281-7_29
Attainment of LDL-cholesterol target in high cardiovascular risk type 1 diabetic French people
Breuker, C., Macioce, V., Lasse, A., Zogheib, M.-L., Cavallin, L., Herman, F., Picot, M., Gourdy, P., Sallerin, B., Avignon, A., et al. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101568
Global Perspective of Cardiovascular Disease in Women
Maas, A. H. E. M., & Gerdts, E. (2024) · Springer eBooks · doi:10.1007/978-3-031-65952-2_1
Fredriksson, M., Persson, E., Möllsten, A., & Lind, T. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004709
Özde, Ş., Yavuzyılmaz, F., Özel, M. A., Kayapınar, O., Özde, C., Aktüre, G., & Arslanoğlu, İ. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030935
Paediatric Type 1 Diabetes Still Remains a Challenge
Persson, M. (2025) · Paediatric and Perinatal Epidemiology · doi:10.1111/ppe.13180
Holmgren, J., Englund, E., Carlsson, A., Litwin, L. C., Weismann, C. G., Odermarsky, M., & Liuba, P. (2025) · Acta Paediatrica · doi:10.1111/apa.70002
“Type 1 diabetes is a well-known risk factor for the development of atherosclerosis, with the further increased risk of cardio-vascular disease in those affected in the first decade of life [9].”
Noori, N. M., Teimouri, A., & Sardo, S. G. (2025) · Journal of Comprehensive Pediatrics · doi:10.5812/jcp-157062
Metabolic Associations between Cardiovascular Disease, Diabetes and Kidney Disease
王, 佳. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.152491
Blais, J. E., Yan, V. K. C., Chan, E. W., Wong, I. C. K., & Wan, E. Y. F. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5159870
Metadata
- Authors
- Rawshani, A., Sattar, N., Franzén, S., Rawshani, A., Hattersley, A. T., Svensson, A.-M., Eliasson, B., & Gudbjörnsdottir, S.
- Affiliations
- Sahlgrenska University Hospital (SE)
- University of Glasgow (GB)
- Region Västra Götaland (SE)
- University of Exeter (GB)
- University of Gothenburg (SE)
- Corresponding author
- Rawshani, Araz
- Sattar, Naveed
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 392
- Issue
- 10146
- Pages
- 477-486
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC6828554
- OpenAlex
- W2887373570
- Cited by
- 802
- References
- 40
- Citations by year
- 2026: 81 · 2025: 103 · 2024: 113 · 2023: 108 · 2022: 101 · 2021: 114 · 2020: 105 · 2019: 67 · 2018: 9
- FWCI
- 58.64
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Open Research Exeter (University of Exeter) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Figshare (submittedVersion)
- Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion)
- Funders
- Hjärt-Lungfonden
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, age at diagnosis, excess mortality, cardiovascular disease, cardiovascular mortality, coronary artery disease, heart failure, atrial fibrillation, acute myocardial infarction, stroke, young adults, risk stratification, diabetes duration, non-cardiovascular mortality, Swedish National Diabetes Register, sex differences in mortality
- MeSH terms
- Adolescent, Adult, Age Factors, Cardiovascular Diseases, Child, Child, Preschool, Diabetes Mellitus, Type 1, Female, Humans, Infant, Infant, Newborn, Male, Registries, Sweden, Cohort Studies, Proportional Hazards Models, Age of Onset, Diabetes Complications, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review